Takeda has just put the last regulatory piece in place for its $62 billion takeover of Shire. The European Commission has provided its blessing for the deal, with one requirement.
As expected, Takeda will have to divest SHP647 so it can retain its blockbuster drug Entyvio, where the Europeans saw an overlap. The other regulators involved in the US and Japan have already signed off.
Now there’s just one last obstacle to clear as CEO Christophe Weber looks to vault past a group of dissident Japanese shareholders and complete the journey into the top ranks of industry players.
The shareholder vote comes December 5, with a band of holdouts — including members of the Takeda family — vowing to fight to the end. If the vote goes Webber’s way, the deal will close January 8, right in the middle of JPMorgan.
Noted Weber today:
We are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.
Image: Christophe Weber, Takeda CEO Getty Images
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.Free Subscription